Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>CEL-SCI is developing two platforms: Multikine and LEAPS.</li><li>Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer.</li><li> In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the low PD-L1, non-chemotherapy population.</li></ul>

CEL-SCI is developing two platforms: Multikine and LEAPS.Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer. In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the low PD-L1, non-chemotherapy population.

CVM: CRO Selected for Registrational Trial

<ul><li>CEL-SCI is developing two platforms: Multikine and LEAPS.</li><li>Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer.</li><li> In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the non-chemotherapy population.</li></ul>

CEL-SCI is developing two platforms: Multikine and LEAPS.Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer. In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the non-chemotherapy population.

CVM: Start Your Engines - FDA Green Lights Confirmatory Registration Study

<ul><li>CEL-SCI is developing two platforms: Multikine and LEAPS. Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer.</li><li> In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the non-chemotherapy population.</li><li>CEL-SCI plans to submit applications in the US, EU, UK and Canada.</li></ul>

CEL-SCI is developing two platforms: Multikine and LEAPS. Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer. In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the non-chemotherapy population.CEL-SCI plans to submit applications in the US, EU, UK and Canada.

United States

CEL-SCI Corporation operates as a biotechnology company. The Company engages in the research and development of immunotherapy products for the treatment of cancer, autoimmune, and infectious diseases. CEL-SCI offers its services across North America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CEL-SCI (CVM US)

CVM: CRO Selected for Registrational Trial

CEL-SCI is developing two platforms: Multikine and LEAPS. Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is...

Zacks Small Cap Research

CVM: Start Your Engines - FDA Green Lights Confirmatory Registration Study

CEL-SCI is developing two platforms: Multikine and LEAPS. Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is...

Zacks Small Cap Research

CVM: Confirmatory Study Clarity

CEL-SCI is developing two platforms: Multikine and LEAPS. Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)